These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34046709)

  • 1. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.
    Daldrup-Link HE; Theruvath AJ; Rashidi A; Iv M; Majzner RG; Spunt SL; Goodman S; Moseley M
    Pediatr Radiol; 2022 Feb; 52(2):354-366. PubMed ID: 34046709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
    Adams LC; Jayapal P; Ramasamy SK; Morakote W; Yeom K; Baratto L; Daldrup-Link HE
    AJR Am J Roentgenol; 2023 Apr; 220(4):590-603. PubMed ID: 36197052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
    Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
    Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.
    Theruvath AJ; Aghighi M; Iv M; Nejadnik H; Lavezo J; Pisani LJ; Daldrup-Link HE
    Nanotheranostics; 2020; 4(4):195-200. PubMed ID: 32637297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
    Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
    Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
    Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
    Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
    Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
    AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
    Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
    Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
    Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
    Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.
    Muehe AM; Siedek F; Theruvath AJ; Seekins J; Spunt SL; Pribnow A; Hazard FK; Liang T; Daldrup-Link H
    Theranostics; 2020; 10(8):3612-3621. PubMed ID: 32206111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidental ferumoxytol artifacts in clinical brain MR imaging.
    Bowser BA; Campeau NG; Carr CM; Diehn FE; McDonald JS; Miller GM; Kaufmann TJ
    Neuroradiology; 2016 Nov; 58(11):1087-1091. PubMed ID: 27704163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
    Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
    Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferumoxytol magnetic resonance imaging detects joint and pleural infiltration of bone sarcomas in pediatric and young adult patients.
    Theruvath AJ; Rashidi A; Nyalakonda RR; Avedian RS; Steffner RJ; Spunt SL; Daldrup-Link HE
    Pediatr Radiol; 2021 Dec; 51(13):2521-2529. PubMed ID: 34410452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
    Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW
    Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging applications for ferumoxytol as a contrast agent in MRI.
    Bashir MR; Bhatti L; Marin D; Nelson RC
    J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol.
    Shahrouki P; Khan SN; Yoshida T; Iskander PJ; Ghahremani S; Finn JP
    Pediatr Radiol; 2022 Mar; 52(3):501-512. PubMed ID: 34936018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ferumoxytol vs gadolinium on 4D flow cardiovascular magnetic resonance measurements in small children with congenital heart disease.
    Kollar SE; Udine ML; Mandell JG; Cross RR; Loke YH; Olivieri LJ
    J Cardiovasc Magn Reson; 2022 Nov; 24(1):58. PubMed ID: 36352454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia.
    Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C
    Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.